Avantor (AVTR): Assessing Undervaluation After Recent Sector Weakness

Avantor (AVTR) shares saw a modest move today as investors weighed ongoing shifts in the broader life sciences sector. With choppy returns over the past month, the market seems to be taking a wait-and-see approach.

See our latest analysis for Avantor.

After a challenging stretch that saw a 1-month share price return of -24.01%, Avantor shares are attempting to find their footing. Momentum has faded significantly this year, with the share price down 45.66% year-to-date and the 1-year total shareholder return sitting at an equally steep -44.56%. This signals that investors remain cautious about near-term growth and sector headwinds but may also be watching for signs of a turnaround.

If you're looking to discover other companies in the healthcare space showing different momentum, it might be time to browse our latest picks using the See the full list for free..

Despite recent declines, Avantor's current share price is below analyst targets. This may reflect both sector challenges and company-specific risks. Does this signal an undervalued opportunity, or has the market already priced in all future growth?

Most Popular Narrative: 15.6% Undervalued

Avantor’s most widely followed narrative sets its fair value at $13.64, notably higher than the last close at $11.52. This gap draws attention to underlying drivers that challenge current market pessimism and hints at strong long-term catalysts at play.

The continued acceleration of biologics, gene therapies, and personalized medicine creates an increasing need for specialized and single-use solutions. Avantor is investing in market-leading platforms and expanding innovation in this area, positioning the company to benefit from secular end-market growth and a product mix shift toward higher-margin segments, supporting margin and earnings growth.

Read the complete narrative.

Ever wondered why analysts see potential upside even amid all the red on the chart? The answer comes down to bold bets on future margins and a major shift in business focus. Want to know the hidden numbers shaping this fair value estimate and the bullish assumptions driving it? The full narrative reveals the must-read details.

Result: Fair Value of $13.64 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent margin pressures and sluggish recovery in bioprocessing demand could limit Avantor's ability to deliver on turnaround expectations.

Find out about the key risks to this Avantor narrative.

Build Your Own Avantor Narrative

If the current story does not resonate with you or you prefer to dig into the numbers yourself, you can craft your own perspective in just a few minutes using our tools. Do it your way.

A great starting point for your Avantor research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Ready for Your Next Big Opportunity?

Stay ahead of the market and uncover fresh opportunities. Some of today’s most exciting investment ideas are just a click away on our screener.

• Unlock high returns by targeting the best-yielding income picks when you check out these 17 dividend stocks with yields > 3%.
• Catalyze your portfolio with these 25 AI penny stocks that are pushing the boundaries of technology and artificial intelligence right now.
• Tap into future innovations by scanning these 26 quantum computing stocks to spot pioneers building the quantum computing landscape.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com